A5036906585- Adenosine and Purinergic Signaling
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Pancreatitis Pathology and Treatment
- Adolescent and Pediatric Healthcare
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
- Phagocytosis and Immune Regulation
- CAR-T cell therapy research
- Nanoplatforms for cancer theranostics
- Inflammatory Biomarkers in Disease Prognosis
- Pancreatic function and diabetes
- Radiopharmaceutical Chemistry and Applications
- Advanced biosensing and bioanalysis techniques
- Renal and related cancers
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
The University of Texas Health Science Center at Houston
2022-2024
Pancreatic ductal adenocarcinoma (PDAC) presents a 5-year overall survival rate of 11%, despite efforts to improve clinical outcomes in the past two decades. Therapeutic resistance is hallmark this disease, due its dense and suppressive tumor microenvironment (TME). Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) promising local ablative potential immunomodulatory therapy for PDAC. In study, we performed RFA preclinical tumor-bearing KrasG12D; Trp53R172H/+; Pdx1:Cre (KPC)...
Abstract The microenvironment that surrounds pancreatic ductal adenocarcinoma (PDAC) is profoundly desmoplastic and immunosuppressive. Understanding triggers of immunosuppression during the process tumorigenesis would aid in establishing targets for effective prevention therapy. Here, we interrogated differential molecular mechanisms dependent on cell origin subtype promote PDAC initiation established tumors. Transcriptomic analysis cell-of-origin–dependent epithelial gene signatures...
Pancreatitis is currently the leading cause of gastrointestinal hospitalizations in US. This condition occurs response to abdominal injury, gallstones, chronic alcohol consumption or, less frequently, remains idiopathic. CD73 a cell surface ecto-5'-nucleotidase that generates extracellular adenosine, which can contribute resolution inflammation by binding adenosine receptors on infiltrating immune cells. We hypothesized genetic deletion would result more severe pancreatitis due decreased...
Pancreatic ductal adenocarcinoma presents a 5-year overall survival rate of 11%, placing an imperative need for the discovery and application innovative treatments. Radiofrequency ablation represents promising therapy PDA, as studies show it induces coagulative necrosis host adaptive immune response. In this work we evaluated effects RFA treatment
Immunoprevention is an emerging consideration for solid tumors, including pancreatic ductal adenocarcinoma (PDAC). We and others have shown that Kras mutations in genetic models of spontaneous intraepithelial neoplasia (PanIN), which a precursor to PDAC, results CD73 expression the neoplastic epithelium some populations infiltrating immune cells, macrophages CD8 T cells. ecto-enzyme converts extracellular adenosine monophosphate adenosine, critical inhibitory molecule PDAC. hypothesized...
ABSTRACT Background and Aims Pancreatitis is currently the leading cause of gastrointestinal hospitalizations in US. This condition occurs response to abdominal injury, gallstones, chronic alcohol consumption or, less frequently, remains idiopathic. CD73 a cell surface ecto-5’-nucleotidase that generates extracellular adenosine, which can contribute resolution inflammation by binding adenosine receptors on infiltrating immune cells. We hypothesized genetic deletion would result more severe...
ABSTRACT Background and Aims Pancreatic ductal adenocarcinoma (PDAC) is characterized by resistance to therapy. A major contributing factor therapeutic failure profound desmoplasia a well-documented hypoxic tumor microenvironment (TME). In PDAC, several approaches, including chemotherapy radiation alone or combined with immune checkpoint inhibitors, have shown minimal success, placing an imperative need for the discovery application of innovative treatments. Endoscopic ultrasound guided...
<p>Supplementary Figure S2. AB-680 treatment significantly alters the gene expression profiles of each identified cluster.</p>
<p>Supplementary Figure S3. CD73 inhibitor treatment does not significantly change Granzyme B or B3GAT1 levels.</p>
<div>Abstract<p>Immunoprevention is an emerging consideration for solid tumors, including pancreatic ductal adenocarcinoma (PDAC). We and others have shown that Kras mutations in genetic models of spontaneous intraepithelial neoplasia (PanIN), which a precursor to PDAC, results CD73 expression the neoplastic epithelium some populations infiltrating immune cells, macrophages CD8 T cells. ecto-enzyme converts extracellular adenosine monophosphate adenosine, critical inhibitory...
<p>Supplementary Figure S5. Treatment with a CD73 small molecule inhibitor does not change AMP or inosine levels in pancreas tissue serum.</p>
<p>Supplementary Figure S1. Description of IHC quantification methods.</p>
<p>Supplementary Figure S4. AB-680 treatments results in distinct changes gene expression macrophages, dendritic cells and naïve T cells.</p>
<p>Supplementary Figures S1-9</p>
<div>Abstract<p>Pancreatic ductal adenocarcinoma (PDAC) presents a 5-year overall survival rate of 11%, despite efforts to improve clinical outcomes in the past two decades. Therapeutic resistance is hallmark this disease, due its dense and suppressive tumor microenvironment (TME). Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) promising local ablative potential immunomodulatory therapy for PDAC. In study, we performed RFA preclinical tumor-bearing...
<p>Supplementary Figures S1-9</p>
<p>Supplementary Figures S1-9</p>